Boundless Bio (BOLD) Return on Capital Employed (2024 - 2026)
Boundless Bio (BOLD) posted quarterly Return on Capital Employed of 43.52% for Q1 2026, down 522.0% year-over-year from 10.31% in Q1 2025, and down 2.97% quarter-over-quarter from 42.27% in Q4 2025.
Boundless Bio (BOLD) Return on Capital Employed (2024 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Return on Capital Employed for 3 consecutive years, with 43.52% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 522.0% year-over-year to 43.52%; the TTM figure through Mar 2026 stood at 43.52% (down 522.0% YoY), while the FY2025 annual figure was 37.56%, up 823.0% from the prior year.
- Return on Capital Employed declined to 43.52% in Q1 2026 per BOLD's latest filing, from 42.27% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 38.3% in Q1 2025 and bottomed at 52.81% in Q1 2024.
- Historically, Return on Capital Employed has averaged 42.74% across 3 years, with a median of 41.81% in 2025.
- Annual changes were most pronounced in 2025 — Return on Capital Employed soared 1451 bps — and 2026, when it slumped 522 bps.
- Boundless Bio's Return on Capital Employed stood at 40.12% in 2024, then fell by 5 bps to 42.27% in 2025, then retreated by 3 bps to 43.52% in 2026.
- Business Quant data shows BOLD's Return on Capital Employed at 43.52% in Q1 2026, 42.27% in Q4 2025, and 41.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Boundless Bio | 67.35 Mn | 67.35 Mn | - | -68.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -68.29% |
| Mar 31, 2026 | -43.52% |
| Dec 31, 2025 | -42.27% |
| Sep 30, 2025 | -41.81% |
| Jun 30, 2025 | -40.53% |
| Mar 31, 2025 | -38.30% |
| Dec 31, 2024 | -40.12% |
| Sep 30, 2024 | -40.08% |
| Jun 30, 2024 | -45.25% |
| Mar 31, 2024 | -52.81% |